Share on LinkedInShare on LinkedIn

ARTICLE · 31 JANUARY 2025

Amgen And Celltrion Settle Denosumab BPCIA Case

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement...

United StatesIntellectual Property

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding Celltrion's denosumab biosimilar, CT-P41. Pursuant to the agreement, Celltrion will be enjoined from making, using, selling, or importing CT-P41 into the U.S. market until June 1, 2025.

Celltrion submitted its BLA for CT-P41 to the FDA on November 30, 2023, referencing Amgen's PROLIA and XGEVA. Amgen filed suit against Celltrion on May 28, 2024, asserting 29 patents. In the Consent Judgment, Celltrion agreed that all 29 patents were valid, enforceable, and infringed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from